SHL – ABN Amro rates the stock as Hold

The result was slightly below consensus but solid nevertheless, the broker reports. Sonic has picked up market share and management has reaffirmed better than 10% expected growth for FY09. A successful consclusion to the next Australian Pathology Memorandum of Understanding is a positive catalyst to look forward to in May, the broker notes. Target falls from $14.20 to $13.50. Sector: Health Care Equipment and Services.

Read More